NRx Pharmaceuticals Starts Commercial Production of Preservative-Free Ketamine

Key Facts

NRx Pharmaceuticals has officially initiated the commercial manufacturing process for its preservative-free ketamine formulation, following guidance from the FDA. The company transmitted an initial GMP manufacturing order to its US-based facility, marking a significant operational milestone. This development follows the successful completion of confirmatory GMP audits, positioning the firm for upcoming pre-approval inspections by regulatory authorities. By moving into the production phase, NRx Pharmaceuticals aims to streamline its path toward market entry and commercial availability. Investors are viewing this as a positive step for the micro-cap biotech firm as it executes its generic drug strategy. The transition to active manufacturing underscores the company's commitment to meeting stringent regulatory standards and clinical demand.